Common Stock, par value $0.0001 per share
- Symbol
- RNAZ
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
TransCode Therapeutics, Inc.
RNAZNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 28, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing updated clinical data from its Phase 1a dose clinical trial of TTX-MC138. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Company context
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.
Current securities
Recent company filings
- 3 filingSep 21, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
- 10-Q filingAug 14, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAug 3, 2026
- SCHEDULE 13G filingJul 28, 2026
Registered securities in this filing
TRANSCODE THERAPEUTICS, INC. · 8-K · Filed 2026-09-28
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 28, 2026, TransCode Therapeutics,
Inc. (“TransCode”) issued a press release announcing updated clinical data from its Phase 1a dose clinical trial of TTX-MC138.
A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors In the 14 efficacy-evaluable patients: o 71.4% stable disease rate o 57.1% of patients had disease control through three months of therapy o 36.7% maintained disease control through six months of therapy o Three efficacy-evaluable patients remain progression-free at one year Exploratory blood RNA-sequencing showed treatment-associated antitumor immune activation and biological features associated with stable disease. The primary endpoint of the study was met o No dose-limiting toxicities were reported across the evaluated dose levels BOSTON, MA, September 28, 2026 - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced updated clinical data from its Phase 1a clinical trial of TTX-MC138, its novel anti-miR-10b therap…
Open exhibit ↗